相关实验视频
Updated: Jan 11, 2026

09:42
Comprehensive Analysis of Drug Response using the FLICK Assay
Published on: June 6, 2025
685
药物诱导冲击不良反应的挖掘和分析:基于美国FAERS数据库的综合药监测研究
Junhua Lai1, YiPing Pan1, JunTao Hu1
1Intensive Care Unit, The First Affiliated Hospital of Guangxi Medical University, NanNing, GuangXi, China.
PloS one
|November 13, 2025
概括
这项药监测研究确定了与休克相关的关键药物类别,包括心血管,抗感染和神经系统药物. 先进的多方法信号检测提高了识别高风险药物和组合的准确性,以更好地管理临床风险.
科学领域:
- 药物监督 药物监督 药物监督
- 药品安全 药品安全
- 临床药理学 临床药理学
背景情况:
- 冲击是一种具有高死亡率的危急状态.
- 药物诱导性休克是一种复杂的不良药物反应,需要进行系统的调查.
- 大规模的药物监测对于识别高风险药物和组合药物至关重要.
研究的目的:
- 进行药物诱导性休克的综合药监测分析.
- 为了识别与休克相关的特定药物和药物组合.
- 评估多方法信号检测在药监监管中的有效性.
主要方法:
- 对FDA不良事件报告系统 (FAERS) 数据 (2004-2024) 的回顾性分析.
- 使用了四种信号检测方法:ROR,PRR,IC和EBGM.
- 应用解剖治疗化学物质 (ATC) 分类和 Ω 收缩,用于药物相互作用分析.
主要成果:
- 分析了8,511,840份医疗保健专业人员的报告,在244,030名患者中确定了277,956起与冲击有关的事件.
- 心血管药物 (32%),抗感染药物 (28%) 和神经系统药物 (23%) 与休克有显著的关联.
- 确定了高风险组合,包括阿纳斯托 + 列沃素和杜洛西丁 + 翁丹塞.
结论:
- 特定的药物类别,特别是心血管,抗感染和神经系统药物,与冲击有很强的联系.
- 多方法信号检测显著提高了药监准确性.
- 这些发现为临床监测和药物诱导性休克风险管理提供了关键证据.
相关概念视频
Pharmacovigilance
1.6K
Post-marketing surveillance is a critical component of pharmaceutical regulation, often uncovering unanticipated adverse drug reactions (ADRs) once a drug is widely used over an extended period.
This process, termed pharmacovigilance, aims to detect, evaluate, and minimize harmful effects related to medication use. The data collection for pharmacovigilance depends on spontaneous reporting systems, where healthcare professionals or patients voluntarily report suspected ADRs.
In some cases, there...
This process, termed pharmacovigilance, aims to detect, evaluate, and minimize harmful effects related to medication use. The data collection for pharmacovigilance depends on spontaneous reporting systems, where healthcare professionals or patients voluntarily report suspected ADRs.
In some cases, there...
1.6K
Drug Regulation
2.7K
Drug regulation encompasses the management of drug usage by evaluating its safety and efficacy through assessments conducted by regulatory authorities. Regrettably, the history of drug regulation is marred by several catastrophic events. One such incident is the Elixir Sulfanilamide tragedy, in which the toxic compound diethyl glycol was included in a sweet-tasting medication, leading to numerous fatalities. This event prompted the enactment of the Food, Drug, and Cosmetic Act in 1938. Under...
2.7K
Therapeutic Drug Monitoring: Affecting Factors
189
Therapeutic Drug Monitoring (TDM) is the clinical practice of measuring specific drug levels in a patient's blood or body tissues to manage and optimize therapy. TDM is crucial for drugs with narrow therapeutic windows, like warfarin and phenytoin, where incorrect doses can lead to treatment failure or severe side effects. This monitoring ensures the dosage administered is within a safe and effective range. The factors affecting therapeutic drug monitoring include:Patient-Specific Factors:a.
189
Therapeutic Drug Monitoring: Drug Analysis Methods
168
Therapeutic Drug Monitoring (TDM) is a clinical practice that measures specific drug levels in a patient's blood or body tissues to tailor drug therapy effectively. This monitoring is critical for managing drugs with narrow therapeutic indices like digoxin and phenytoin, ensuring they are both safe and effective. For instance, monitoring theophylline levels in asthma patients involves precision and sensitivity to adjust doses according to individual responses to therapy, ensuring efficacy and...
168
Measurement of Bioavailability: Pharmacodynamic Methods
225
Pharmacodynamic methods provide insights into a drug's effects on physiological processes over time and play a crucial role in understanding bioavailability and therapeutic efficacy. These methods can be broadly classified into acute pharmacological and therapeutic response approaches, each with distinct mechanisms and applications.The acute pharmacological response method directly correlates a drug's physiological effects, such as ECG or pupil diameter changes, to its time course in the body.
225
FDA Approved Drugs: Changes to Approved Drugs
236
Post-approval, manufacturers may modify an approved new or generic drug product. Such modifications can encompass alterations in the Active Pharmaceutical Ingredient (API), manufacturing process, formulation, batch size, manufacturing site, and container closure system (FDA Guidance for Industry, April 2004). Often, a drug product may undergo multiple changes.These modifications require careful evaluation to determine their potential impact on the drug product's identity, strength, quality,...
236

